Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Prognostic value of 18F-FDG-PET/CT parameters in patients with pancreatic carcinoma: A systematic review and meta-analysis.

Zhu D, Wang L, Zhang H, Chen J, Wang Y, Byanju S, Liao M.

Medicine (Baltimore). 2017 Aug;96(33):e7813. doi: 10.1097/MD.0000000000007813. Review.

2.

Para-aortic lymph node metastases in pancreatic cancer should not be considered a watershed for curative resection.

Hempel S, Plodeck V, Mierke F, Distler M, Aust DE, Saeger HD, Weitz J, Welsch T.

Sci Rep. 2017 Aug 9;7(1):7688. doi: 10.1038/s41598-017-08165-w.

3.

Contrast-enhanced CT in determining resectability in patients with pancreatic carcinoma: a meta-analysis of the positive predictive values of CT.

Somers I, Bipat S.

Eur Radiol. 2017 Aug;27(8):3408-3435. doi: 10.1007/s00330-016-4708-5. Epub 2017 Jan 16.

4.

Surveillance for neoplasia in the pancreas.

Overbeek KA, Cahen DL, Canto MI, Bruno MJ.

Best Pract Res Clin Gastroenterol. 2016 Dec;30(6):971-986. doi: 10.1016/j.bpg.2016.10.013. Epub 2016 Nov 5. Review.

6.

MR and CT imaging characteristics and ablation zone volumetry of locally advanced pancreatic cancer treated with irreversible electroporation.

Vroomen LGPH, Scheffer HJ, Melenhorst MCAM, de Jong MC, van den Bergh JE, van Kuijk C, van Delft F, Kazemier G, Meijerink MR.

Eur Radiol. 2017 Jun;27(6):2521-2531. doi: 10.1007/s00330-016-4581-2. Epub 2016 Sep 22.

7.

Liquid Biopsies for Assessing Metastatic Melanoma Progression.

Huynh K, Hoon DS.

Crit Rev Oncog. 2016;21(1-2):141-54. doi: 10.1615/CritRevOncog.2016016075.

8.

Eastern Canadian Colorectal Cancer Consensus Conference 2013: emerging therapies in the treatment of pancreatic, rectal, and colorectal cancers.

Di Valentin T, Asmis T, Asselah J, Aubin F, Aucoin N, Berry S, Biagi J, Booth CM, Burkes R, Coburn N, Colwell B, Cripps C, Dawson LA, Dorreen M, Frechette D, Goel R, Gray S, Hammad N, Jonker D, Kavan P, Maroun J, Nanji S, Roberge D, Samson B, Seal M, Shabana W, Simunovic M, Snow S, Tehfe M, Thirlwell M, Tsvetkova E, Vickers M, Vuong T, Goodwin R.

Curr Oncol. 2016 Feb;23(1):52-5. doi: 10.3747/co.23.2897. Epub 2016 Feb 18.

9.

The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.

Yapp DT, Wong MQ, Kyle AH, Valdez SM, Tso J, Yung A, Kozlowski P, Owen DA, Buczkowski AK, Chung SW, Scudamore CH, Minchinton AI, Ng SS.

Angiogenesis. 2016 Apr;19(2):229-44. doi: 10.1007/s10456-016-9503-z. Epub 2016 Mar 9.

10.

Preoperative Volume-Based PET Parameter, MTV2.5, as a Potential Surrogate Marker for Tumor Biology and Recurrence in Resected Pancreatic Cancer.

Kang CM, Lee SH, Hwang HK, Yun M, Lee WJ.

Medicine (Baltimore). 2016 Mar;95(9):e2595. doi: 10.1097/MD.0000000000002595.

11.

The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients.

Jung W, Jang JY, Kang MJ, Chang YR, Shin YC, Chang J, Kim SW.

HPB (Oxford). 2016 Jan;18(1):57-64. doi: 10.1016/j.hpb.2015.06.001. Epub 2015 Dec 21.

12.

Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer.

Pimiento JM, Davis-Yadley AH, Kim RD, Chen DT, Eikman EA, Berman CG, Malafa MP.

Clin Nucl Med. 2016 Mar;41(3):177-81. doi: 10.1097/RLU.0000000000001098.

13.

Combining in Vitro Diagnostics with in Vivo Imaging for Earlier Detection of Pancreatic Ductal Adenocarcinoma: Challenges and Solutions.

Laeseke PF, Chen R, Jeffrey RB, Brentnall TA, Willmann JK.

Radiology. 2015 Dec;277(3):644-61. doi: 10.1148/radiol.2015141020.

14.

Imaging preoperatively for pancreatic adenocarcinoma.

Pietryga JA, Morgan DE.

J Gastrointest Oncol. 2015 Aug;6(4):343-57. doi: 10.3978/j.issn.2078-6891.2015.024. Review.

15.

Circulating Cell-Free Tumour DNA in the Management of Cancer.

Francis G, Stein S.

Int J Mol Sci. 2015 Jun 19;16(6):14122-42. doi: 10.3390/ijms160614122. Review.

16.

PET/CT Fusion Scan Prevents Futile Laparotomy in Early Stage Pancreatic Cancer.

Kim R, Prithviraj G, Kothari N, Springett G, Malafa M, Hodul P, Kim J, Yue B, Morse B, Mahipal A.

Clin Nucl Med. 2015 Nov;40(11):e501-5. doi: 10.1097/RLU.0000000000000837.

17.

Consequences of additional use of contrast-enhanced (18)F-FDG PET/CT in target volume delineation and dose distribution for pancreatic cancer.

Li XX, Liu NB, Zhu L, Yuan XK, Yang CW, Ren P, Gong LL, Zhao LJ, Xu WG, Wang P.

Br J Radiol. 2015 Jul;88(1051):20140590. doi: 10.1259/bjr.20140590. Epub 2015 May 5.

18.

A prospective study of the impact of fluorodeoxyglucose positron emission tomography with concurrent non-contrast CT scanning on the management of operable pancreatic and peri-ampullary cancers.

Burge ME, O'Rourke N, Cavallucci D, Bryant R, Francesconi A, Houston K, Wyld D, Eastgate M, Finch R, Hopkins G, Thomas P, Macfarlane D.

HPB (Oxford). 2015 Jul;17(7):624-31. doi: 10.1111/hpb.12418. Epub 2015 Apr 30.

19.

Cancer stratification by molecular imaging.

Weber J, Haberkorn U, Mier W.

Int J Mol Sci. 2015 Mar 4;16(3):4918-46. doi: 10.3390/ijms16034918. Review.

20.

Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer.

Wang XY, Yang F, Jin C, Fu DL.

World J Gastroenterol. 2014 Nov 14;20(42):15580-9. doi: 10.3748/wjg.v20.i42.15580. Review.

Supplemental Content

Support Center